{"name": "Pathway Therapeutics",
 "permalink": "pathway-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/pathway-therapeutics",
 "homepage_url": "http://pathwaytx.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@pathwaytx.com",
 "phone_number": "",
 "description": "",
 "created_at": "Thu May 26 02:50:24 UTC 2011",
 "updated_at": "Mon Jun 17 11:23:53 UTC 2013",
 "overview": "\u003Cp\u003EPathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       57],
      "assets/images/resized/0013/6498/136498v2-max-150x150.jpg"],
     [[250,
       96],
      "assets/images/resized/0013/6498/136498v2-max-250x250.jpg"],
     [[320,
       123],
      "assets/images/resized/0013/6498/136498v2-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Julie",
      "last_name": "Cherrington",
      "permalink": "julie-cherrington",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$24.4M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://pathwaytx.com/reference/PR_June_18_2008.pdf",
    "source_description": "$10million for Pathway cancer drugs",
    "raised_amount": 9600000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 6,
    "funded_day": 18,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "CM Capital Investments",
         "permalink": "cm-capital-investments",
         "image":
          {"available_sizes":
            [[[150,
               43],
              "assets/images/resized/0006/1273/61273v1-max-150x150.png"],
             [[250,
               73],
              "assets/images/resized/0006/1273/61273v1-max-250x250.png"],
             [[342,
               100],
              "assets/images/resized/0006/1273/61273v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "GBS Ventures",
         "permalink": "gbs-ventures",
         "image":
          {"available_sizes":
            [[[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-150x150.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-250x250.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "http://pathwaytx.com/reference/PR_Oct_9_2009.pdf",
    "source_description": "Pathway Therapeutics Completes $3Million Financing for Cancer Programs and appoints Dr Julie Cherrington as Chief Executive Officer",
    "raised_amount": 2400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 10,
    "funded_day": 9,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "GBS Ventures",
         "permalink": "gbs-ventures",
         "image":
          {"available_sizes":
            [[[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-150x150.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-250x250.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "CM Capital Investments",
         "permalink": "cm-capital-investments",
         "image":
          {"available_sizes":
            [[[150,
               43],
              "assets/images/resized/0006/1273/61273v1-max-150x150.png"],
             [[250,
               73],
              "assets/images/resized/0006/1273/61273v1-max-250x250.png"],
             [[342,
               100],
              "assets/images/resized/0006/1273/61273v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "http://pathwaytx.com/reference/PR_Aug_10_2010.pdf",
    "source_description": "Pathway Therapeutics Completes $4.5 Million Financing for Novel PI3K Inhibitor Portfolio",
    "raised_amount": 4500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 8,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "GBS Ventures",
         "permalink": "gbs-ventures",
         "image":
          {"available_sizes":
            [[[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-150x150.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-250x250.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "CM Capital Investments",
         "permalink": "cm-capital-investments",
         "image":
          {"available_sizes":
            [[[150,
               43],
              "assets/images/resized/0006/1273/61273v1-max-150x150.png"],
             [[250,
               73],
              "assets/images/resized/0006/1273/61273v1-max-250x250.png"],
             [[342,
               100],
              "assets/images/resized/0006/1273/61273v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "New Zealand Venture Investment Fund",
         "permalink": "new-zealand-venture-investment-fund",
         "image":
          {"available_sizes":
            [[[150,
               35],
              "assets/images/resized/0010/2841/102841v1-max-150x150.jpg"],
             [[235,
               56],
              "assets/images/resized/0010/2841/102841v1-max-250x250.jpg"],
             [[235,
               56],
              "assets/images/resized/0010/2841/102841v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "http://pathwaytx.com/reference/PR_%20May%2025%202011%20press%20release%20%20FINAL.pdf",
    "source_description": "FDA Approves Trial of Pathway Therapeutics, Inc. Cancer Drug; $7.5 Million Financing in Place to Advance Novel PI3K/mTOR Inhibitor Portfolio",
    "raised_amount": 7500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 5,
    "funded_day": 25,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "GBS Ventures",
         "permalink": "gbs-ventures",
         "image":
          {"available_sizes":
            [[[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-150x150.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-250x250.png"],
             [[100,
               74],
              "assets/images/resized/0004/8580/48580v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "CM Capital Investments",
         "permalink": "cm-capital-investments",
         "image":
          {"available_sizes":
            [[[150,
               43],
              "assets/images/resized/0006/1273/61273v1-max-150x150.png"],
             [[250,
               73],
              "assets/images/resized/0006/1273/61273v1-max-250x250.png"],
             [[342,
               100],
              "assets/images/resized/0006/1273/61273v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "debt_round",
    "source_url": "http://www.sec.gov/Archives/edgar/data/1498495/000149849513000001/xslFormDX01/primary_doc.xml",
    "source_description": "SEC",
    "raised_amount": 400000.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 3,
    "funded_day": 5,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "409 Illinois Street",
    "address2": "",
    "zip_code": "94158",
    "city": "San Francisco",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": 37.7666288,
    "longitude": -122.3879774}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        100],
       "assets/images/resized/0013/6499/136499v1-max-150x150.jpg"],
      [[250,
        166],
       "assets/images/resized/0013/6499/136499v1-max-250x250.jpg"],
      [[450,
        300],
       "assets/images/resized/0013/6499/136499v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}